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Summary
Background: Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15) concentration has been associated with colonic adenomas and carcinoma.
Aims: To determine whether circulating MIC-1/GDF15 serum concentrations are higher in the presence of adenomas and whether the level decreases after excision.
Methods: Patients were recruited prospectively from a single centre and stratified into five groups: no polyps (NP); hyperplastic polyps (HP); sessile serrated ademona (SSA); adenomas (AP); and colorectal carcinoma (CRC). Blood samples were collected immediately before and 4 weeks after colonoscopy. MIC-1/GDF15 serum levels were quantified using ELISA.
Results: Participants (n=301) were stratified as: NP; n=116 (52%), HP; n=37 (12%), SSA; n=19 (7%), AP; n=68 (23%); and CRC; n=3 (1%). Patients were excluded from the study due to nondiagnostic pathology (n=9, 3%) and exclusion criteria (n=20, 6%). In the 272 remaining subjects (M=149; F=123), age (P=.005), history of colonic polyps (P=.003) and family history of colonic polyps (P=.002) were associated with presence of adenomas. Baseline median MIC-1/GDF15 serum levels increased significantly from NP 609 (460-797) pg/mL, HP 582 (466-852) pg/mL, SSA 561 (446-837) pg/mL to AP 723 (602-1122) pg/mL and CRC 1107 (897-1107) pg/mL; (P<.001). In the pre-and postpolypectomy paired adenoma samples median MIC-1/ GDF15 reduced significantly from 722 (603-1164) pg/mL to 685 (561-944) pg/mL (P=.002). A ROC analysis for serum MIC-1/GDF15 to identify adenomatous polyps indicated an area under the curve of 0.71.
Conclusions:
Our data suggest that serum MIC-1/GDF15 has the diagnostic characteristics to increase the detection of colonic neoplasia and improve screening.
| BACKGROUND AND AIMS
Macrophage inhibitory cytokine-1 (MIC-1/GDF15) is a promising biomarker for the presence of colonic neoplasia. This multifunctional cytokine, a divergent member of the transforming growth factor beta (TGF-b) superfamily is thought to be involved in the regulation of inflammation, metabolism and tumourigenesis. [1] [2] [3] [4] [5] [6] [7] Unusually for a cytokine, MIC-1/GDF15 is present in the circulation of all individuals in substantial amounts with a normal serum concentration of 150-1150 pg/mL. 8 Serum levels increase in various disease processes such as injury, inflammation and malignancy and are also stimulated
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*Contributed equally by nonsteroidal anti-inflammatory drugs. 2, 5, [7] [8] [9] [10] [11] [12] [13] In some disease states such as congestive cardiac failure, renal failure and advanced malignancy, serum levels may rise by 10-100 fold and contribute to the development of anorexia/cachexia. 23 Studies of MIC-1/GDF15 and carcinogen-induced colon and lung cancers both also support its protective role. 21, 24 In colorectal cancer, the simultaneous elevation of local MIC-1/ GDF15 expression with changes in colonic mucosa and epithelial dysplasia also support its use as a biomarker. 2, 8, 20, 25, 26 There are data to suggest that serum levels may increase progressively from normal intestinal mucosa, to adenomatous polyps and further in established malignancy. 8, 27 Several studies also support the potential for serum MIC-1/GDF15 levels to predict colon cancer 25, 26 and data are starting to emerge on its role in the diagnosis of colonic polyps.
In serial sampling, a progressive rise in MIC-1/GDF15 was associated with an increased relative risk of developing colorectal neoplasia. 2 In a retrospective analysis of blood taken from subjects in the Polyp Prevention Trial serial serum MIC-1/GDF15 levels predicted the presence or recurrence of colonic polyps. 2 However, the results of the study were limited by a high variation in the timing of blood sampling and polyp detection.
Another important limitation of the use of MIC-1/GDF15 as a biomarker is a wide normal serum range. Hence, there is potential for a several-fold elevation in serum level before exceeding the normal range. This may be overcome by serial sampling. As a simple and noninvasive screening tool, serial monitoring of MIC-1/GDF15 serum levels has the potential to predict the presence of high-risk colonic polyps and improve stratification of endoscopic surveillance. The clinical utility of MIC-1/GDF15 as a biomarker may be more accurately gauged by studying its serum levels pre-and postexcision of high-risk polyps. The aims of this study were to determine whether circulating MIC-1/GDF15 serum concentrations are higher in the presence of colonic adenomas and if the levels of the biomarker subsequently decrease after the excision of adenomatous polyps. where MIC-1/GDF15 comes from a pathological source. 29 The MIC-1/GDF15 serum levels were assayed in duplicate using a sandwich enzyme-linked immunosorbent assay (ELISA), which has previously been described. 7, 30 The median MIC-1/GDF15 serum level for each sample was extrapolated from a standard curve constructed using the software GraphPad Prism (Version 6, La Jolla, CA, USA). A coefficient of variation < 12% was deemed acceptable.
| METHODS
Statistical analyses were performed using Stata Statistical Soft- 
| RESULTS
A total of 301 participants were stratified as follows: (1) NP (n=116, 52%) as the control group, (2) HP (n=37, 12%), (3) SSA (n=19, 7%), (4) AP (n=68, 23%) and (5) CRC (n=3, 1%), outlined in Figure 1 . Subjects (n=20; 7%) who had both adenomatous and hyperplastic or sessile serrated polyps and were classified as AP for the purpose of this study. Patients were excluded from the study due to nondiagnostic pathology (n=9, 3%), a CV ≥12% (n=10, 3%) and exclusion criteria recognised postrecruitment (n=10, 3%) leaving 272 subjects for analysis. A postendoscopic blood sample was successfully obtained from 49% of subjects with HP (n=18; median=52 days), 47% of subjects with SSA (n=9; median=49 days) and 66% of subjects with AP (n=45; median=43 days). A second fasting blood sample was also requested and obtained from 10 participants in whom no polyps were identified (7%; median=36 days). Figure 1 outlines the study enrolment and follow-up. (IQR 561-944) pg/mL (P=.002) after the removal of polyps. Figure 3 summarises the median change in serum level for the no adenoma, SSA and AP subsets, respectively (+12 vs +10 vs À37 pg/mL; P<.02).
| Study population characteristics

| Receiver operating characteristic (ROC) curve
for the capacity of MIC-1/GDF15 to identify adenomatous polyps MIC-1/GDF15 serum levels reflected the presence of colonic adenomas. This was illustrated using a receiver operating characteristic (ROC) curve for the capacity of MIC-1/GDF15 to identify adenomatous polyps, outlined in 
| CONCLUSIONS
Our results demonstrate that MIC-1/GDF15 serum levels are increased in colonic adenomas (P<.001) and decrease following removal of the adenoma (P<.002), suggesting that colonic neoplasia directly contributes to circulating serum MIC1/GDF15 levels. This finding is consistent with our understanding of the biomarker and the study hypothesis. While MIC-1/GDF15 is not specific to colonic epithelium, 31 in subjects with colonic adenomas, serum levels dropped by a median 37 pg/mL as compared to the no adenoma group who displayed a nonsignificant average increase of 12 pg/mL.
This implies that the cytokine is able to enter the circulation to cause a detectable change in serum concentration.
These results are consistent with previous studies where the mean serum MIC-1/GDF15 level at baseline is significantly higher in the presence of adenomas as compared to NP and HP. 2, 8 In our study, the lack of a significant statistical difference between the serum levels in the NP and HP groups aligns with our understanding that MIC-1/GDF15 serum levels are only significantly increased by Regular NSAID use defined as ≥ once per week with no use in the 7 days prior to colonoscopy. In our study, there was no impact of colonoscopy procedural factors on MIC1/GDF15 levels. We studied the impact of bowel preparation in paired samples and found no significant difference in serum levels of MIC1/GDF15 between pre-endoscopic and postendoscopic samples 515 (IQR 424-662) pg/mL vs. 527 (IQR 417-669) pg/mL (P=.41) in subjects without polyps. Furthermore, diathermy and snare polypectomy had no significant effect on MIC-1/GDF15 serum levels because there was no difference in pre-and postendoscopic levels for the hyperplastic polyp group in which non-adenomatous polyps were removed by the same means. Therefore, the change in serum MIC-1/GDF15 is due to the removal of the adenoma rather than other interventional factors.
We demonstrated an association between increased MIC-1/ GDF15 serum levels and a past history of colonic polyps (P=.003).
As a significant proportion of our study cohort had a previous history of polyps (106/272, 39%), this may have contributed to higher MIC-1/GDF15 serum concentrations at baseline as compared to the earlier study that used unselected cohorts. MIC-1/GDF15 has the potential to identify subjects at increased risk of having colonic adenomas and could better individualise colonoscopy interval surveillance. In addition, MIC-1/GDF15 is likely to resolve the shortcomings of current techniques given that a blood test is readily acceptable to the population, carries low risk and might be more cost-effective than FOBT or endoscopic surveillance. 36 As MIC-1/GDF15 is not specific to malignancy or the gastrointestinal tract, the intra-individual variation in the serum level is likely to be more useful than a cross-sectional measure for colonic Author contributions: MD, DB, DB and SB conceptualised the study, recruited the patients, analysed the data and wrote the paper.
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